Alleh Lindquist At Benzinga CCC Says At FloraWorks We're Looking At Natural Derivative Compounds From The Plant As Well As Derivatives And Event To The Point Of Creating New Cannabinoid Compounds Structured To Optimize Therapeutic Outcomes
Portfolio Pulse from Benzinga Newsdesk
Lindquist at Benzinga CCC stated that FloraWorks is focusing on natural derivative compounds from plants, as well as derivatives, and even creating new cannabinoid compounds structured to optimize therapeutic outcomes.
September 27, 2023 | 3:22 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The news does not directly mention MSOS, but the company's focus on cannabinoid compounds could indirectly affect MSOS, an ETF that tracks the performance of US-listed companies in the cannabis industry.
While the news does not directly mention MSOS, the ETF could be indirectly affected due to its exposure to the cannabis industry. If FloraWorks' efforts in developing new cannabinoid compounds prove successful, it could potentially boost the overall industry, positively impacting MSOS. However, the impact is uncertain and indirect, hence the neutral score.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50